Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment

被引：0

作者：

Genovese, Mark C. ^{[1
]}

van Hoogstraten, Hubert ^{[2
]}

St John, Gregory ^{[3
]}

Dong, Qunming ^{[2
]}

Jose Gomez-Reino, Juan ^{[4
]}

Maldonado-Cocco, Jose A. ^{[5
]}

Carlos Salazar, Juan ^{[6
]}

Huizinga, Tom W. J. ^{[7
]}

Burmester, Gerd R. ^{[8
]}

机构：

[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[2] Sanofi Genzyme, Bridgewater, NJ USA

[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[4] Complejo Hosp Univ Santiago de Compostela, Santiago, Spain

[5] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina

[6] Riesgo Fractura SA CAYRE, Bogota, Colombia

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] Charite Univ Med Berlin, Berlin, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2509

引用

页数：3

共 50 条

[41] Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
Senbel, Eric
Durand, Frederick
Roux, Baptiste
Badaoui, Fatima-Zohra
Fautrel, Bruno
[J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 921 - 935
[42] Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis
Fleischmann, Roy
Koenig, Andrew S.
Szumski, Annette
Nab, Henk W.
Marshall, Lisa
Bananis, Eustratios
[J]. RHEUMATOLOGY, 2014, 53 (11) : 1984 - 1993
[43] TREATMENT WITH BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) FOR RHEUMATIC DISEASE AT A MELBOURNE PUBLIC HOSPITAL: BASELINE CHARACTERISTICS AND PRE-TREATMENT SCREENING
Pourhadi, Hedayat
Foote, Andrew
[J]. INTERNAL MEDICINE JOURNAL, 2022, 52 : 38 - 38
[44] DISEASE ACTIVITY, COMORBIDITIES AND FUNCTIONAL STATUS PREDICT TREATMENT RESPONSE TO BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PSORIATIC ARTHRITIS
Addae-Kyereme, Christine
Lembke, Stephanie
Macfarlane, Gary J.
Jones, Gareth T.
[J]. RHEUMATOLOGY, 2023, 62
[45] Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis
Sener, Seher
Aliyev, Emil
Batu, Ezgi Deniz
Balik, Zeynep
Bayindir, Yagmur
Cam, Veysel
Basaran, Ozge
Bilginer, Yelda
Ozen, Seza
[J]. CLINICAL RHEUMATOLOGY, 2024, 43 (06) : 2021 - 2026
[46] Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
Lubrano, Ennio
Scriffignano, Silvia
Perrotta, Fabio Massimo
[J]. RHEUMATOLOGY AND THERAPY, 2023, 10 (02) : 301 - 306
[47] Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
Ennio Lubrano
Silvia Scriffignano
Fabio Massimo Perrotta
[J]. Rheumatology and Therapy, 2023, 10 : 301 - 306
[48] The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs
Radner, Helga
Yoshida, Kazuki
Frits, Michelle
Iannaccone, Christine
Shadick, Nancy A.
Weinblatt, Michael
Smolen, Josef S.
Solomon, Daniel H.
[J]. RHEUMATOLOGY, 2015, 54 (11) : 2076 - 2084
[49] Combined treatment with leflunomide and methotrexate for patients with disease-modifying anti-rheumatic drugs naive active rheumatoid arthritis
Lee, S.
Park, Y.
Kang, Y.
Nam, E.
Kim, S.
Lee, J.
Yoo, W.
Lee, S.
Park, J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 342 - 342
[50] Factors predictive of treatment success of novel disease-modifying anti-rheumatic drugs (DMARDS) in patients with inflammatory arthritis
Overbeek, Jetty A.
Herings, Ron
Moens, Hein J. Bernelot
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 229 - 229

← 1 2 3 4 5 →